gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · MEDPTechnologyR&D — Physical & Biological Sciences

Medpace Holdings, Inc. Common Stock (MEDP)

$634.98−3.32%
Close Nov 5, 2026 · split-adjusted
Nov 3, 2026$671.63▲ 13.06% in range
Nov 3, 2025Low $393.42 · High $692.68Nov 3, 2026
What changed · written from our data
As of Nov 5, 2026

Medpace Holdings closed at $634.98 on Nov 5, down 3.32%, 8.3% below its 52-week closing high. Volume of 316.2K shares was 0.96× its 20-day average (close to normal).

Split-adjusted performance: +5.1% over one month, +48.1% over six months, +6.8% over one year.

In the quarter ended Sep 30, 2026, revenue was $716M, up 8.5% from a year earlier, with a net margin of 19.2%.

Short interest was 1.6M shares at the Oct 15 settlement, up 1.0% from the prior report (7.2% of float, 6.6 days to cover).

Market cap$17.76B28.0M shares
Revenue · quarter$716.0M+8.5% YoY
Diluted EPS$4.84+25.4% YoY
P/E · TTM34.3×P/S 6.3×
Net margin19.2%Gross 31.3%
Dividend yieldNone
52-week range393.42 – 692.68−8.3% from high
Volume316.2K0.96× 20-day avg
Volatility · 60d30.4%Annualised
Short % of float7.2%6.6 days to cover
Net cash$705.3MCash $705.3M
Next earnings—Not scheduled
Split-adjusted performance
1W −6.3%1M +5.1%3M +7.5%6M +48.1%YTD +13.1%1Y +6.8%3Y +161.7%5Y +189.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within R&D — Physical & Biological Sciences

Percentile among 11 companies (100 = best)

6-month momentum50
Revenue growth50
Net margin100
Value (low P/E)—
Size80

Industry medians: 6-month return +48.1%, revenue growth +8.5%, net margin −122.0%, P/E 47.0×.

Short interest

Details →
Shares short1.6M+1.0% vs prior
Days to cover6.6Settled Oct 15
% of float7.2%
Short vol. 10d57.5%of daily volume

Closest peers by size in R&D — Physical & Biological Sciences

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
MEDPMedpace Holdings$634.98−3.32%+48.1%+8.5%19.2%34.3$17.76B
CRLCharles River Laboratories International$313.02−4.07%+72.3%−2.7%−0.1%—$15.00BCompare
INCYIncyte Genomics$118.01−3.94%+20.7%+14.0%−50.4%59.6$24.05BCompare
IQVIQVIA Holdings$264.88+0.41%+48.3%+8.0%7.9%31.3$43.65BCompare
ABSIAbsci$9.39−10.40%+63.3%−46.4%−10443.4%—$1.61BCompare
OABIOmniAb$4.83−6.76%+228.6%+78.3%−393.9%—$704.5MCompare
NRCNRC Health$25.48−5.87%+36.0%+11.0%12.3%88.2$540.7MCompare
MXCTMaxCyte$1.31−5.76%+50.3%−14.5%−122.0%—$135.2MCompare
IBACIB Acquisition$10.81−0.46%−0.2%———$54.1MCompare

News about Medpace Holdings

All news →
Medpace (MEDP) is a Great Momentum Stock: Should You Buy?Zacks Investment Research · 6d ago▲ PositiveIs Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think "Yes"Zacks Investment Research · Oct 26, 2026▲ PositiveAll You Need to Know About Medpace (MEDP) Rating Upgrade to BuyZacks Investment Research · Oct 26, 2026▲ PositiveMedpace: 3 Key Takeaways for Long-Term InvestorsThe Motley Fool · Oct 23, 2026▲ PositiveMedpace (MEDP) Q3 Earnings and Revenues Beat EstimatesZacks Investment Research · Oct 21, 2026Neutral

Quick answers

What does Medpace Holdings do?
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities.
What is MEDP's market cap?
$17.76B, based on the Nov 5 close of $634.98.
What is MEDP's P/E ratio?
34.3× trailing-twelve-month earnings of $517.83M.
Does Medpace Holdings pay a dividend?
No regular cash dividend has been paid in the last year.
How much of MEDP is sold short?
1.6M shares, 7.2% of float, as of Oct 15, 2026.
What sector is MEDP in?
Technology, in the R&D — Physical & Biological Sciences industry.

About Medpace Holdings

Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.

HQ: Cincinnati, OH6,600 employeesListed Aug 11, 2016medpace.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology